Professor of Oncology, Mayo Medical School; Consultant in Medical Oncology, Department of Oncology, Mayo Clinic
Oncology
Dr. Keith C. Bible, MD
|
|
Give Review
Keith Bible is an expert in the field of Oncology. He attended University of Illinois College of Medicine. He has 1 awards "Regional Top Doctor". Doctor Keith C. Bible, MD is a published doctor and has 43 publications published. The lastest was: 'A one-step method for protein estimation in biological samples: nitration of tyrosine in nitric acid.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Surgical resection of synchronously metastatic adrenocortical Cancer.
- Advanced radioiodine-refractory differentiated thyroid Cancer: the sodium iodide symporter and other emerging therapeutic targets.
- Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic CholangioCarcinoma.
- Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
- Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid Cancer: results of a multicenter phase 1 trial.
- Taking Stock of Therapeutic Progress in Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer - What's Next?
- Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid Cancer.
- A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal Carcinoma: MC0261.
- Treating advanced radioresistant differentiated thyroid Cancer.
- Toward improved outcomes in patients with anaplastic thyroid Cancer.
- Enhanced survival in locoregionally confined anaplastic thyroid Carcinoma: a single-institution experience using aggressive multimodal therapy.
- Annatto constituent cis-bixin has selective antimyeloma effects mediated by oxidative stress and associated with inhibition of thioredoxin and thioredoxin reDuctase.
- Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.
- The antiCancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase.
- Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity.
- Chaetocin: a promising new antiMyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress.
- Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity.
- Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy.
- Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic ...
- Dynamics of water transport and storage in conifers studied with deuterium and heat tracing techniques.
- Erratum - " Didemnins and Tunichlorin: Novel Natural ProDucts from the Marine Tunicate Trididemnum solidum.
- The antiCancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation.
- Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian Cancer.
- Effect of P-glycoprotein on flavopiridol sensitivity.
- The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast Cancer resistance protein-mediated ...
- Flavopiridol binds to duplex DNA.
- Characterization of an ovarian carcinoma Cell line resistant to cisplatin and flavopiridol.
- Characterization of caspase processing and activation in HL-60 Cell cytosol under Cell-free conditions. Nucleotide requirement and inhibitor profile.
- A one-step method for protein estimation in biological samples: nitration of tyrosine in nitric acid.
- Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
- Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human Lung carcinoma cells.
- Acyl tunichlorins: a new class of nickel chlorins isolated from the Caribbean tunicate Trididemnum solidum.
- Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and Chronic natural killer cell lymphocytosis.
- Tunichlorin: a nickel chlorin isolated from the Caribbean tunicate Trididemnum solidum.
- Didemnins and tunichlorin: novel natural proDucts from the marine tunicate Trididemnum solidum.
- Gastric ulceration as a complication of hepatic artery infusion chemotherapy.
- Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult Acute leukemias.
- Flavopiridol in patients with relapsed or refractory multiple Myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.
- A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single Oral dose and weekly infusion in p...
- Prosurvival function of the granulin-epithelin precursor is important in tumor progression and chemoresponse.
- Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid Cancers: results of a phase 2 consortium study.
Schools
University Of Illinois College Of Medicine Chicago
Mayo Clinic Rochester
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Mayo School of Graduate Medical Education -
University of Illinois at Urbana-Champaign -
University of Illinois College of Medicine -
Washington University
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1497733216 | |
| NPPES Provider LastName | BIBLE | |
| NPPES Provider FirstName | KEITH | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 534.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 28.0 | |
| Percent Opioid Claims | 5.24 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497733216 |
| Last Name Of The Provider | BIBLE |
| First Name Of The Provider | KEITH |
| View All |
Similar Doctors
|
|
Dr. Janell N. Shaw, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jan C. Buckner, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Patrick A. Burch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul Haluska Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen Frytak, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Joleen M. Hubbard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michaela S. Banck, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy J. Hobday, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manish Kohli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul D. Brown, MD |
|
|
Dr. Timothy J. Moynihan, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Frank A. Sinicrope, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Ivy A. Petersen, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Katharine A. Price, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andreas S. Beutler, MD
This Doctor is OpenDoctor Recommended.
|